PMDA: Necessary Package Insert Revisions from April 2018

被引：0

|

作者：

不详

机构：

来源：

PHARMACEUTICAL MEDICINE | 2018年 / 32卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：299 / 299

页数：1

相关论文

共 50 条

[1] PMDA: necessary package insert revisions from April 2018
Reactions Weekly, 2018, 1700 (1) : 1 - 1
[2] Package insert revisions recommended by PMDA
Reactions Weekly, 2019, 1783 (1) : 6 - 6
[3] Package insert revisions recommended by PMDA
Reactions Weekly, 2017, 1682 (1) : 5 - 5
[4] Recent package insert revisions recommended by PMDA
Reactions Weekly, 2018, 1696 (1) : 3 - 3
[5] PMDA recommends package insert revisions for five products
Reactions Weekly, 2020, 1826 (1) : 4 - 4
[6] Package insert revisions required: Japan's PMDA findings
Reactions Weekly, 2016, 1615 (1) : 4 - 4
[7] Japan's MHLW/PMDA recommends package insert revisions
Reactions Weekly, 2018, 1732 (1) : 1 - 1
[8] PMDA: package insert revisions needed for four drugs in Japan
Reactions Weekly, 2017, 1665 (1) : 1 - 1
[9] Package insert revisions for three therapies in Japan
Reactions Weekly, 2018, 1727 (1) : 3 - 3
[10] Package insert revisions for apremilast, ceftriaxone in Japan
Reactions Weekly, 2018, 1715 (1) : 2 - 2

← 1 2 3 4 5 →